Goldman Sachs
YARW

Goldman Sachs’s Yarrow Bioscience YARW Stock Holding History

Goldman Sachs’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-129
Closed -$118K – 6931
2021
Q4 		$118K Buy
129
+82
+174% +$88K ﹤0.01% 6088
2021
Q3 		$58K Buy
47
+3
+7% +$5.82K ﹤0.01% 6015
2021
Q2 		$141K Sell
44
-6
-12% -$23.7K ﹤0.01% 5863
2021
Q1 		$310K Buy
50
+1
+2% +$7.25K ﹤0.01% 5411
2020
Q4 		$278K Buy
49
+24
+96% +$151K ﹤0.01% 4927
2020
Q3 		$151K Sell
25
-3
-11% -$17.5K ﹤0.01% 5001
2020
Q2 		$177K Buy
28
+12
+75% +$81.3K ﹤0.01% 4833
2020
Q1 		$151K Hold
16
– – ﹤0.01% 4805
2019
Q4 		$266K Buy
16
+6
+60% +$100K ﹤0.01% 4793
2019
Q3 		$167K Sell
10
-1
-9% -$16.1K ﹤0.01% 4864
2019
Q2 		$238K Hold
11
– – ﹤0.01% 4711
2019
Q1 		$301K Buy
11
+1
+10% +$24K ﹤0.01% 4632
2018
Q4 		$148K Buy
10
+2
+25% +$44.8K ﹤0.01% 4911
2018
Q3 		$288K Buy
8
+4
+100% +$123K ﹤0.01% 4743
2018
Q2 		$118K Buy
+4
New +$155K ﹤0.01% 5166

Other funds holding YARW

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return

Goldman Sachs's YARW Position: Q1 2022 in Review

Goldman Sachs sold out of Yarrow Bioscience (YARW) in Q1 2022, closing a stake of 129 shares — an estimated $118K sold.

Goldman Sachs first reported a position in YARW in Q2 2018 and held it in 15 quarters. The position peaked at $310K in Q1 2021. 41 funds tracked by Wall St. Rank hold YARW as of Q1 2022.

  • Goldman Sachs reported no remaining Yarrow Bioscience position as of Q1 2022 after selling out during the quarter.
  • Goldman Sachs sold 129 Yarrow Bioscience shares in Q1 2022, an estimated $118K.
  • Goldman Sachs first reported a position in Yarrow Bioscience in Q2 2018 and held it in 15 quarters.
  • Goldman Sachs's Yarrow Bioscience position peaked at $310K in Q1 2021.
  • 41 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q1 2022.

Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.